Following the 2017 launches of two atopic dermatitis novel therapies, Pfizer’s topical PDE-4 inhibitor Eucrisa (crisaborole) and Sanofi/Regeneron’s IL-4/13 inhibitor Dupixent (dupilumab), the U.S. treatment and market access landscape for atopic dermatitis is evolving. Topical agents are the mainstay of treatment for atopic dermatitis, especially for patients with mild to moderate disease. Eucrisa provides a much needed alternative to topical corticosteroids and topical calcineurin inhibitors. Dupixent has given moderate to severe atopic dermatitis patients a promising targeted therapy option, with AstraZeneca/Leo Pharma’s tralokinumab, Galderma’s nemolizumab, Vanda’s tradipitant, and multiple JAK inhibitors potentially strengthening the field in the near future. Payers look to manage utilization of therapies to control costs in the wake of the more recent premium-priced entrants in this previously genericized market.
QUESTIONS ANSWERED
CONTENT HIGHLIGHTS
Geography: United States
Primary Research: Survey of 100 U.S. dermatologists Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs)
Key Drugs Covered: Dupixent, Eucrisa, Protopic, Elidel, CellCept, Neoral/Sandimmune, Temovate/Olux/Clobex, Aristocort/Kenalog, tralokinumab, nemolizumab, tradipitant, baricitinib, upadacitinib, abrocitinib
Content Highlights: Reimbursement and contracting Access and prescribing Special topics Opportunities and challenges for emerging therapies
PRODUCT DESCRIPTION
U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.